

Sir,
High dosage of oral valaciclovir as an alternative treatment of varicella zoster acute retinal necrosis syndrome

The therapy of varicella zoster virus (VZV) acute retinal necrosis syndrome by oral valganciclovir was recently reported by Savant *et al.*¹ This therapy was given to a 30-year-old woman as an alternative treatment option in herpes viral retinitis. Oral therapy has the great advantage to avoid prolonged intravenous (i.v.) drug administration and hospital admission. Valganciclovir, a L-valyl ester prodrug with improved bioavailability, is hydrolysed in the gut and liver and produces ganciclovir exposure similar to i.v. ganciclovir. Ganciclovir differs from acyclovir by the lack of an hydroxyl group on the acyclic side chain, with enhanced activity against cytomegalovirus (CMV), but similar activity against herpes simplex and VZ virus.² However, this modification is associated with cytotoxicity and serious adverse effects in humans including neutropenia, anaemia, diarrhoea. In addition, it has been shown to be mutagenic, teratogenic, and carcinogenic in animal models. Ganciclovir has also the potential to permanently affect fertility in animal and humans (Product monograph, Roche Basel, CH, Switzerland).

Indeed, ganciclovir and valganciclovir are exclusively registered for the treatment of life or sight-threatening CMV infections.

Our treatment option in acute retinal necrosis syndrome is rather high dosage oral valaciclovir. The L-valylester valaciclovir offers an oral bioavailability of 54.2%, which is about 4.5 times higher than oral aciclovir. The recommended dosage in VZV infection is valaciclovir 1000 mg t.i.d. that produces AUC similar to i.v. aciclovir at the dosage of 5 mg/kg t.i.d. However, pilot clinical studies could demonstrate that higher dosage of oral valaciclovir 2000 mg 4 times daily could produce the daily AUC of 109 µg h, which was close to the one obtained by i.v. aciclovir at the dosage of 10 mg/kg t.i.d. (AUC of 107 mg h).³ The limit of the administration of high dosage of valaciclovir is mostly the renal and CNS toxicity of the drug that can be avoided by adequate hydration and dose adjustment to creatinine clearance. These high valaciclovir dosages have been indeed well tolerated when prescribed to kidney transplant recipients for the prophylaxis of CMV disease, with only a slight excess in CNS adverse effects such as hallucination and confusion.^{4,5} We suggest that higher dosage of oral valaciclovir could be a good alternative therapy to i.v. aciclovir.

References

- 1 Savant V, Saeed T, Denniston A, Murray PI. Oral valganciclovir treatment of varicella zoster virus acute retinal necrosis. *Eye* 2004; **18**: 544.
- 2 Smee DF, Martin JC, Verheyden JPH, Matthews TR. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. *Antimicrob agents chemother* 1983; **23**: 676.
- 3 Curran M, Noble S. Valganciclovir. *Drugs* 2001; **61**: 1145–1150.
- 4 Perry CM, Faulds S. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. *Drugs* 1996; **52**: 754–772.
- 5 Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ *et al.* Valaciclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valaciclovir Cytomegalovirus Prophylaxis Transplantation Study Group. *N Engl J Med* 1999; **340**: 1462–1470.

Y Guex-Crosier¹ and PR Meylan²

¹Jules Gonin Eye Hospital, 15 av. de France, CH-1004 Lausanne, Switzerland

²Institute of Microbiology and Service of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, CH-1004 Lausanne, Switzerland

Correspondence: Y Guex-Crosier
Tel: +41 21 6268230;
Fax: +41 21 6268122.
E-mail: yan.guex@ophthal.vd.ch

Eye (2006) **20**, 247. doi:10.1038/sj.eye.6701821;
published online 18 March 2005

Sir,
Characteristics and surgical outcomes of paediatric retinal detachment

Yokoyama *et al* have given us an insight into the characteristics and aetiology of rhegmatogenous retinal detachment (RRD) in paediatric population. Interestingly, among the 49 patients, no one suffered from rhegmatogenous retinal detachment as a result of retinopathy of prematurity (ROP) while up to 13% of cases were attributed to an uncommon retinal disease, familial exudative vitreoretinopathy (FEVR).¹ This spectrum of diseases pattern, however, showed deviation from what have been observed by previous studies.^{2,3}

In an observation of 29 eyes in 27 paediatric RRD patients, Fivgas and Capone² had shown that myopia was reckoned as the most common aetiology (34%, 10/29 eyes) with nearly half of the myopic patients labelled as having ROP-related detachments. In the present study, authors did not provide any subgroup analysis and it is not certain how many cases were actually in association with ROP, which is not an uncommon retinal disorders in the prematurity paediatric population.

Conversely, familial exudative vitreoretinopathy (FEVR) is a comparatively uncommon paediatric retinal disorder.³ A proportion of 13% among other causes for paediatric RRD may be disproportionately high in comparison with other series.² Retinal detachment associated with FEVR may not necessarily be rhegmatogenous in nature, which has been found to be responsible for only 57.1% of RD cases whereas exudative together with tractional RD accounted for the remaining 42.9%.³ In lack of further breakdown of the data and ascertainment of the inclusion criteria, we were wondering the possibility of combined RD such as rhegmatogenous and tractional or rhegmatogenous and exudative entities instead of pure RRD being recruited into the study.

Authors can certainly enlighten us in these regards.

Acknowledgements

Financial and proprietary interest: Nil.

Financial Support: Nil

References

- 1 Yokoyama T, Kato T, Minamoto A, Sugihara A, Imada M, Kuwabara R *et al*. Characteristics and surgical outcomes of paediatric retinal detachment. *Eye* 2004; **18**: 889–892.
- 2 Fivgas GD, Capone Jr A. Pediatric rhegmatogenous retinal detachment. *Retina* 2001; **21**: 101–106.
- 3 Shukla D, Singh J, Sudheer G, Soman M, John RK, Ramasamy K *et al*. Familial exudative vitreoretinopathy (FEVR). Clinical profile and management. *Indian J Ophthalmol* 2003; **51**: 323–328.

DTL Liu, VYW Lee, W-M Chan and DSC Lam

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, People's Republic of China

Correspondence: DTL Liu, Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, University Eye Center, Hong Kong Eye Hospital, 147 K, Argyle Street, Hong Kong, People's Republic of China
Tel: + 852 26322879;

Fax: + 852 26482943.

E-mail: david_tliu@yahoo.com

Eye (2006) **20**, 247–248. doi:10.1038/sj.eye.6701822;
published online 4 March 2005

Sir,
Reply to DTL Liu *et al*

We appreciate the comments made by Dr David TL Liu.

The diagnosis of familial exudative vitreoretinopathy (FEVR) in our study followed the precedent report by Akabane *et al*,¹ in which it was based on abnormal straightening of the retinal vessels, no history of retinopathy of prematurity (ROP), peripheral areas of retinal nonperfusion, and either present or absent of family history. FEVR is genetically heterogeneous. It is not always an autosomal dominant disorder and sporadic cases without family history have been described.² Many individuals have asymptomatic abnormal vascular hypermeability, demonstrable only by fluorescein angiography. It is likely that the frequency has been underestimated. Based on similar diagnostic criteria, FEVR composed 12–16%^{1,3} of cases of juvenile rhegmatogenous retinal detachment in Japanese population, which are comparable to our report.

As we stated in the Patients and methods section, we excluded rhegmatogenous retinal detachments secondary to ROP from our study. We intended to state that not only retinal detachment due to acute ROP but also ROP-related detachments in school-aged children were also excluded. Therefore, no ROP-related detachment was included in the myopic patients in our study.

References

- 1 Akabane N, Yamamoto S, Tsukahara I, Ishida M, Mitamura Y, Yamamoto T *et al*. Surgical outcomes in juvenile retinal detachment. *Jpn J Ophthalmol*. 2001; **45**: 409–411.
- 2 Miyakubo H, Hashimoto K, Miyakubo S. Retinal vascular pattern in familial exudative vitreoretinopathy. *Ophthalmology* 1984; **91**: 1524–1530.
- 3 Miyakubo H, Inohara N, Hashimoto K. Familial exudative vitreoretinopathy and its relationship with juvenile retinal detachment. In: Henkind P (ed). *Acta: XXIV International Congress of Ophthalmology*. Philadelphia: Lippincott, 1983 pp 500–504.

A Minamoto and T Yokoyama

Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences,